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Summary A total of 83 specimens of surgically resected tumours from 78 patients with oesophageal cancer
were assayed for drug sensitivity using an adhesive tumour cell culture system (LifeTrac CSA assay). Seventy-
one of 83 specimens had a sufficient number of cells to permit growth in culture and 57 of 71 (80%) were
evaluable for drug response. Cells (3 x 103 ml-1 well-l) were cultured for 14 days and exposed to drugs on
days 3-8. Growing cells were confirmed as cancer cells by immunohistochemical staining. ICgo values against
several anti-cancer drugs were determined and population distributions of ICgo for each drug served as the
basis for judging sensitivity. The 10th percentiles of IC90 (pg ml-) for CDDP, 5-FU, DOX, CPM, MTX, VP-
16, IFOS, VDS, BLM and CDDP+5-FU were 0.3, 0.16, 0.005, 0.9, 0.006, 0.09, 0.8, 0.006, 0.04 and 0.15+0.09
respectively. The population distribution of IC90 against each drug showed a specific pattern that was very
similar among histopathological gradings and stages of the disease. This system appeared to be a clinically
applicable drug sensitivity test for human oesophageal cancer.
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The therapeutic effect of clinical chemotherapy is mainly
based on the sensitivity of the patient's tumour to the drug;
however, chemosensitivity testing that evaluates the tumour
response before therapy has not yet found widespread clinical
utility. Human tumour clonogenic assay (HTCA) developed
by Hamburger and Salmon (1977) and widely studied all over
the world has been thought to be a reliable chemosensitivity
test. We also used HTCA against human oesophageal cancer,
but found the evaluability rate to be extremely low, leading
us to conclude that HTtA was not so useful for clinical
chemosensitivity testing (Terashima et al., 1992).
Baker et al. (1986) developed a more promising
chemosensitivity test named the adhesive tumour cell culture
system (ATCCS, Lifetrac CSA). ATCCS is a monolayer
culture system based on a culture surface composed of a cell-
adhesive matrix. It is thought that in this system it is possible
to determine drug response against growing cells. The plating
efficiencies of cancer cells from various tumours have been
reported to be high enough to apply this system as a clinical
chemosensitivity test. In addition, Ajani et al. (1987) reported
that this assay predicted clinical response or lack of response
in about 90% of patients tested. To evaluate the clinical
applicability of this assay system to oesophageal cancer, the
concentration of the drugs that produced 90% reduction of
cell viability (ICyo) values of individual resected primary
tumours or dissected lymph nodes for each drug were
analysed by LifeTrac CSA.
Materials and methods
Tumours
A total of 83 fresh surgically resected specimens were
obtained from patients with squamous cell carcinoma of the
oesophagus from 11 institutes. Tumour samples were washed
with sterile physiological saline (PS) and transported to SRL
Inc. in transport medium consisting of alpha modified Eagle
medium (MEM) (Kohjin Bio, Japan) supplemented with 10%
horse serum (Gibco), 500 uml-' penicillin and 500 u ml-'
streptomycin (Gibco). The study was approved by each
Regional Committee- of Ethics. Informed consent was
obtained from all patients.
Drugs
The concentrations of chemotherapeutic agents used in
ATCCS are shown in Table I. Human bone marrow cell
cultures were used to determine the in vitro concentration
range of drugs with a modified bilayer soft agar system as
described by Fan et al. (1987). The four drug concentrations
used for each drug were a 6-32-fold span which covered the
IC50 (low, L) to ICgo (very high; VH) range for granulocyte-
macrophage colony-forming cells (GM-CFC). 4-
Hydroperoxycyclophosphamide and 4-hydroperoxyisopho-
sphamide were used as active forms of cyclophosphamide
(CPM) and ifosphamide (IFOS) respectively.
ATCCS
Solid tumours were minced to 1 mm pieces and then
disaggregated to single cells by incubation with 0.75%
collagenase type 3 (Worthington Bio.) and 0.005% DNAase
(Sigma Chemical) in alpha MEM medium plus 10% horse
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serum for 16 h with constant shaking. The yield of viable
cells was determined by the trypan blue dye exclusion test.
The cell suspension was diluted by addition of 0.6%
methylcellulose (Aldrich) to the medium. Then 24-well plates
were inoculated with a cell inoculum titration consisting of
3000, 1500, 1000, 750, 600 and 375 cells per well in the
control plates and 3000 cells per well in the remaining plates.
After a 24 h incubation, the medium was aspirated and the
adhesive cells were washed with phosphate-buffered saline
(PBS; Gibco) and refed with alpha MEM containing 10%
horse serum, 10 ,ug ml-1 transferrin (Sigma), 0.5 ug ml-'
hydrocortisone (Sigma), 5 ng ml-' epidermal growth factor
(Collaborative Bio), 0.27 jug ml-' oestradiol (Sigma) and
5 ,ug ml-' insulin (Collaborative Bio). The plates were
incubated in a humidified atmosphere of 5% carbon dioxide
for 13 days. Drugs were added to the culture on day 3 and
removed by medium exchange on day 8, resulting in a 5 day
exposure period. We chose continuous 5 day drug exposure
to allow cell cycle-specific agents adequate time to exert their
effects. All cultures were refed by 100% medium exchange on
day 8. At the end of the incubation period, the cultures were
fixed in 70% ethanol for 20 min and stained with 0.05%
crystal violet (Merck, Germany).
In this system, cell survival was estimated by quantitating
the total crystal violet staining density (CSD) of cultures
using an image processor-analyser (Luzex IIIU, Nirevo,
Japan). This method accurately determined the number of
cells in each culture. We were then able to estimate survival
by comparing the total growth potential of treated and
untreated cultures.
Evaluation of assay results
Cell survival for control and experimental cultures deter-
mined quantitatively from stain density measurements made
by an image processor-analysis system. After subtraction of
blank (without cells) CSD values, extrapolated control values
were determined by linear extrapolation of a 'best fit' line,
since overplating indicated a plateau in growth at higher cell
inocula. The value extrapolated to an inoculum of 3000 cells
was used as the 100% untreated value. The survival curves
were plotted and ICgo values were determined.
Cytological studies
Cultured cells were harvested by trypsinisation and collected
by the cytospin method. These specimens were fixed with
ethanol and stained with Papanicolaou stain.
Immunohistochemical studies were also performed against
the same specimen by peroxidase-anti-peroxidase (PAP)
method (Sternberger et al., 1970) using monoclonal antibody
against cytokeratin, vimentin and fibroblast (Dako Corp.).
Cancer cells were determined by morphological features and
reactivity against monoclonal antibodies; positive for
cytokeratin and negative for vimentin and fibroblast.
Statistical analysis
Cross-reactivity between drugs was analysed by linear
regression method by personal computer using the Stat
View (Abacus Concepts) computer program.
Results
Tumour growth and evaluability rate
A total of 83 specimens surgically resected from 78 patients
with oesophageal cancer were assayed for drug sensitivity.
Seventy-one of them had a sufficient number of cells to grow
in culture and 57 out of 71 (80%) were evaluable. However,
14 assays were unevaluable owing to low growth (11),
overgrowth (1) and contamination with fungus (2). Cytolo-
gical studies of the cells after 14 days' cultivation were
performed on 30 samples which were randomly assigned from
57 samples. The population ofcancer cells was determined by
morphological features and immunohistochemical staining.
Cancer cells should be antibody-positive for cytokeratin and
antibody-negative for vimentin and fibroblast whereas
mesenchymal cells should show the opposite pattern. Figure
la shows the typical morphology of the colonies of cancer
cells obtained from moderately differentiated squamous cell
carcinoma. Large nucleated polygonal cells form pavement
arrangements. Figure lb shows the positive immunoreactivity
of the same sample for cytokeratin. Almost all samples were
a mixture of cancer cells and fibroblasts; however, the
populations of cancer cell were predominant in all samples
tested and the populations of fibroblast were so small as to
be almost negligible in 21 out of 30 samples tested.
Drug sensitivities determined by ATCCS
Profiles of IC90 values determined by ATCCS for various
anti-cancer drugs varied from patient to patient. Cumulative
frequency distribution of IC90 values of various drugs against
oesophageal cancer is shown in Figure 2. Population
distribution of IC90 showed specific patterns for each drug.
However, in general there seemed to be two peaks.
Considerable population accumulated in the 'off scale'
range, namely highly resistant cells. This tendency was most
obvious in bleomycin (BLM). In order to evaluate the
therapeutic efficacy of these drugs, the in vitro area under the
curve (AUC) calculated from the tenth percentile of IC90
value was compared with previously reported in vivo AUC
which was expressed as the level when administered with
standard dosage in each drug (Alberts and Chen, 1980).
Figure 1 (a) Typical morphology of the colonies of cancer cells
after 14 days' cultivation obtained from moderately differentiated
squamous cell carcinoma. Large nucleated polygonal cells form
pavement arrangements. (b) The positive immunoreactivity of the
same sample for cytokeratin.Drug sensit testing for oesophageal cancer
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Tenth percentile was the cut-off concentration at which the
10% of tumours were judged as sensitive in each drug. Table
II summarises the 10th percentile and median of IC,, values
and compares the calculated in vitro AUCs with the in vivo
AUCs. The 10th percentile of IC90 values varied extensively
from drug to drug. However, the in vitro. AUC was very
similar to the in vivo AUC in CPM, 5-fluorouracil (5-FU),
vindesine (VDS) and BLM. In other drugs except for cis-
platinum (CDDP), the in vitro AUC was lower than the in
vivo AUC. In CDDP, however, the in vitro AUC was 20
times higher than the in vivo AUC.
Figure 3 shows the frequency distribution of ICG90 values
according to the histopathological gradings of the obtained
tumours. There were no differences in the distribution of ICgo
values according to the histopathological gradings of the
tumour. Similarly, there were no differences in the
distribution of ICG90 values according to the characteristics
of the tumours (data not shown).
The correlation between the ICGo values of two specific
drugs on individual tumours was analysed and correlation
values (r) were listed in Table III. Two drug comparisons:
doxorubicin (DOX) vs etoposide (VP-16) and CPM vs IFOS
correlated relatively well with a correlation value of more
than 0.7. In addition, the sensitivity of mixed CDDP and 5-
FU correlated better with that of 5-FU than that of CDDP.
BLM and VDS seemed to have poor correlation with other
agents.
Discussion
The major reason that in vitro drug sensitivity testing is not
applied clinically is owing to the low reliability of the assay
system. In order to apply drug sensitivity testing clinically, high
evaluability rates and sufficient clinical predictability are
necessary. But in almost all in vitro drug sensitivity tests,
overgrowth offibroblasts is inevitable and the growth ofthese
mesenchymal cells may complicate interpretation of the
chemosensitivity results. In this study the evaluability rate for
oesophageal cancer was very high at 83%, and most of the
Table I Drug concentrations employed in the ATCCS for human oesophageal cancer
Concentration (jigmrl)
Drugs L M H VfJa
Doxorubicin (DOX) 0.0025 0.005 0.01 0.015
cis-Platinum (CDDP) 0.125 0.25 0.5 0.75
Cyclophosphamide (CPM) 0.5 1.0 2.0 3.0
5-Fluorouracil (5-FU) 0.08 0.16 0.32 0.48
Methotrexate (MTX) 0.004 0.008 0.016 0.024
Etoposide (VP-16) 0.04 0.08 0.16 0.24
Ifosphamide (IFOS) 0.5 1.0 2.0 3.0
Vindesine (VDS) 0.001 0.002 0.008 0.016
Bleomycin (BLM) 0.0125 0.025 0.05 0.075
aL, low; M, middle; H, high; VH, very high. The fourdrugconcentrations used for each
drug were a 6- to 32-fold span which covered the IC50 (low) to IC90 (very high) range for
granulocyte-macrophage colony-forming cells (GM-CFC) as described by Fan et al.
(1987).
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Figure 2 Cumulative frequency distributions of IC90 values of various drugs for oesophageal cancer. Off means the IC90 values
more than 10 times that of 'L' concentration listed in Table I. In the mixture of CDDP + 5-FU dose scale indicates the relative drug
concentration as compared with 'L' concentration listed in Table I.
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Table II Tenth percentile and median of cumulative IC90 values and comparisons of calculated in
vitro AUC and previously reported in vivo AUC
Concentration (igmrl-) AUC fighmrl)
Drugs No. Tenth percentilea Median In vitro (10%) In vivoc
DOX 42 0.004398 0.010943 0.528 3.84
CDDP 57 0.307856 0.685084 36.94 1.94
CPM 42 0.904375 1.628925 108.5 118.62
5-FU 57 0.159118 0.290333 19.09 16.33
MTX 52 0.005813 0.009907 0.698 5.34
VP-16 52 0.083943 0.258144 10.07 121.01
IFOS 42 0.826735 1.556250 99.20 3175
VDS 52 0.000571 0.002213 0.069 0.193
BLM 42 0.039323 <0.150000 4.710 4.99
Mix 54
CDDP 0.150738 0.263526
5-FU 0.096427 0.168657
aTenth percentile was the cut-offconcentration that the 10% of tumours werejudged as senstitive in
each drug. bIn vitro AUCs were calculated by drug concentration of 10th percentile of IC90 xdrug
exposure time (120h). CIn vitro AUCs were exposed as the levels when administered with standard
dosages in each drug (Alberts and Chen, 1980).
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Figure 3 Comparison of cumulative frequency distributions of IC90 values of various drugs for oesophageal cancer according to
histological types:, well-differentiated squamous cell carcinoma (GI);, moderately differentiated squamous cell carcinoma (G2);,
poorly differentiated squamous cell carcinoma (G3). Off means the IC90 values are more than ten times that of 'L' concentration
listed in Table I. In the mixture of CDDP+ 5-FU dose scale indicates the relative drug concentration as compared with 'L'
concentration listed in Table I.
Table III Correlation of cross-reactivity between two drugs tested in ATCCS
CDDP/
5-FU BLM VDS IFOS VP-16 MTX 5-FU CPM CDDP
DOX 0.541a 0.461 0.323 0.642 0.738b 0.401 0.560 0.570 0.450
CDDP 0.539 0.218 0.259 0.451 0.468 0.387 0.543 0.215
CPM 0.523 0.249 0.085 0.729 0.471 0.497 0.518
5-FU 0.759 0.224 0.271 0.576 0.551 0.523
MTX 0.534 0.065 0.232 0.400 0.393
VP-16 0.501 0.442 0.384 0.579
IFOS 0.555 0.266 0.237
VDS 0.394 0.141
BLM 0.28
aCorrelation values (r) were calculated by linear regression method. bNumbers in bold indicated a
correlation value ofmore than 0.7.
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growing cells were confirmed as cancer cells by immunohisto-
chemical analysis. Baker et al. (1986) reported that although
the cells grown in ATCCS showed fusiforms that looked like
fibroblasts, thecells were mainlycomposed ofcancercells. This
was confirmed by several morphological and cytogenetic
studies. Parkins and Steel (1990), however, reported that
selective cancer cell growth was not observed in the CAM
plate when compared with conventional tissue culture flasks.
Furthermore, Priceetal. (1991) reported thatsuccessfulgrowth
was obtained only in 41% of the samples and that the
morphology ofthe cultured cells was a mixture ofcancer cells
andfibroblasts. Thediscrepancy in our results may be owing to
differencesin tumourtypesandinthedetails ofourprocedures.
We examined the immunohistochemistry ofa large number of
samples and concluded that almost all growing cells were
cancer cells. Therefore, our drug sensitivity results were based
not on fibroblasts but on cancer cells. Furthermore, we have
previously reported that the sensitivity results obtained from
ATCCS correlated well with another assay system that
suppresses the fibroblast overgrowth using a serum-free
culture system (Terashima et al., 1993).
Several important findings were obtained from our drug
sensitivity data. As the drug sensitivities of oesophageal
cancer varied from patient to patient and the drug sensitivity
patterns for each drug showed a specific pattern, the selection
of chemotherapeutic agents before treatment appeared to be
very important. These drug sensitivities were not dependent
on clinicopathological factors such as the histological grade
of the tumour, making the prediction of drug response from
these factors very diflicult. Furthermore, a considerable
population of the patients fell into the highly resistant range
for each drug. The effect of chemotherapy on these patients
may therefore be limited. The drug sensitivity test appeared
to be a useful tool for eliminating these patients from the
indication of chemotherapy and selecting them for an
alternative treatment method.
To determine the drug sensitivity for each patient in
in vitro drug sensitivity testing, the cut-off level of drug
concentration is very important. Our pharmacokinetic data
revealed that the in vitro calculated AUC of 10th percentile of
IC,0 value well correlated with previously reported in vivo
AUC in almost all drugs tested. However, the in vitro AUCs
were lower than in vivo AUCs in DOX, methotrexate (MTX)
and IFOS, but higher in CDDP. These discrepancies may be
caused by the differences in pharmacokinetics and pharma-
codynamics between in vivo and in vitro condition. In
particular, CDDP, which is thought to be a most potent
agent in clinical chemotherapy, was reported to be
inactivated by binding to human serum albumin (Momburo
et al., 1987), and the instability in culture media was also
investigated (Hiderbrand-Zanki and Kern, 1984). This is the
reason why the in vitro AUC was much higher than in vivo
AUC. To determine the cut-off concentration in in vitro
screening system, the pharmacokinetic and pharmacodynamic
data should be taken into consideration in each drug.
It is important to know the cross-reactivity of drugs to
plan the clinical combination chemotherapy. In this study,
the sensitivity for DOX and VP-16 correlated well. These
agents are known to be topoisomerase II inhibitors, so this
result may suggest the influence of topoisomerase H on the
sensitivity of these agents. Also the sensitivity for CPM and
IFOS correlated well, this is because of the similarity of the
structure ofcompound. These results are compatible with the
results from basic experiment and indicate the reliability of
this assay system. The key drugs now in clinical chemother-
apy against oesophageal cancer are CDDP and 5-FU
(Kelsen, 1984). The response rate of CDDP/5-FU combina-
tion therapy is about 40% (lizuka et al., 1992). However, the
sequence of drug administration is still controversial. From
our data, sensitivity of a combination of CDDP with 5-FU
correlated better with that of 5-FU than that of CDDP. This
data suggests that the sensitivity ofCDDP/5-FU combination
is mainly dependent on 5-FU sensitivity and that CDDP may
act as a modulator of 5-FU.
From these results ATCCS appeared to be a clinically
applicable drug sensitivity test with high evaluability and
reliability. To confirm the clinical predictability of this
system, further clinical study should be carried out. We are
now planning to apply this system as a predictive drug
sensitivity test using endoscopically biopsied specimens.
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